Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial

• Main Authors: Xiaofei Zhou (Author), Sharon Friedlander (Author), Erik Kupperman (Author), Farhad Sedarati (Author), Shingo Kuroda (Author), Zhaowei Hua (Author), Ying Yuan (Author), Yuka Yamamoto (Author), Douglas V. Faller (Author), Kazue Haikawa (Author), Katsuhiko Nakai (Author), Sharon Bowen (Author), Yi Dai (Author), Karthik Venkatakrishnan (Author)
• Format: Book
• Published: Wiley, 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract The investigational NEDD8‐activating enzyme inhibitor pevonedistat is being evaluated in combination with azacitidine versus single‐agent azacitidine in patients with higher‐risk myelodysplastic syndrome (higher‐risk MDS), higher‐risk chronic myelomonocytic leukemia (higher‐risk CMML), or l...